Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02Fn-YJ0 #HLS #Pharma #Basel #DigitalTransformation

Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and @Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02Kz3T10 #HLS #Pharma #Basel #DigitalTransformation

Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and @Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02J56R10 #HLS #Pharma #Basel #DigitalTransformation

Barbara Argibay Gonzalez, the Vice President and General Manager of Anju's Data Division, shared her thought leadership on leveraging advanced technologies for clinical trial success in a Clinical Research News article. 📖 Drug development is a lengthy, expensive, and complex process, so the stakes and the risks are high. Fortunately, sponsors, CROs, and innovators can now take advantage of clinical business intelligence technologies like TA Scan that can ensure the success of a clinical trial. 💪 From jump-starting early planning, facilitating patient recruitment and retention, streamlining feasibility analysis, leveraging Big Data and AI, to ensuring a diverse patient population, Barbara has great recommendations for innovative solutions. 🧠 Read the full Clinical Research News article here: https://lnkd.in/gmkEEzSk #ClinicalResearch #ClinicalTrials #TrialPlanning #PatientRecruitment #TrialFeasibility #DataScience #TAScan

Navigating the evolving landscape of pharmaceutical innovation requires strategic adaptation, especially as the Inflation Reduction Act goes into effect in the USA and other regulatory agencies place greater emphasis on a drug's therapeutic value to patients. Recent research reveals that, despite potential revenue reductions from Medicare price negotiations, the industry can maintain the current level of drug approvals—provided we approach harnessing cost value strategically. https://lnkd.in/eWwU-sPY

💭 Still reflecting on my time at the EPA congress last week. It was such a great opportunity to engage with peers and learn more about key topics in market access. One of the talks that still lingers in my mind was a panel discussion titled ‘Ways that AI can transform Market Access’. It was a chaired by Sandro Cesaro of AstraZeneca, and involved discussions from Chris Mancill (BMS), Rogerio Ribeiro (Takeda), Saira A. Jan (Blue Cross Blue Shield of New Jersey), and Alexander Bastian (A.M. Pharma and Memo Therapeutics). It was a fascinating discussion and here are my key takeaways:   ⌛ Efficiency: AI offers vast potential to enhance efficiencies across the board. From streamlining HR processes to optimising statistical review, its applications are limitless.   💪 Real World Data Power: The power of real-world data cannot be underestimated. Leveraging the capabilities of AI and the might of RWE can create outputs – such as side effect mapping and adherence insights – which can be used to inform payer decision-making processes, leading to more informed and effective strategies.   🤝 Collaboration is key: Successful AI integration necessitates collaboration both within and across businesses. To ensure acceptability, collaboration between manufacturers and payers on what is deemed the acceptable use of AI is vital to ensuring patient access.   ❗ Risk Awareness: While AI promises great rewards, it's essential to remain mindful of associated risks. From data handling to bias mitigation, transparency is key. Leaving EPA with much food for thought and looking forward to seeing how we might integrate these insights into our work at LCP. I feel excited at the progress I have already seen in AI and am looking forward to seeing how it might be leveraged to revolutionise our approach to market access, foster collaboration, drive efficiencies, and ultimately improve patient outcomes #EPAconf #marketaccess #AI

“The stakes are high: effective cost-value management is not just a matter of financial responsibility but a crucial determinant of patient outcomes and the sustainability of healthcare systems.” In their latest article, Paul Archer, Chief Commercial Strategy Officer; Zachary Heim, Director of Business Analytics, Insights, & Strategy; and Daniel Cummings, Senior Vice President, Global Head of Business Strategy, Insights, & Analytics, dive into how advanced technologies like AI and data analytics are transforming the life sciences industry. Key insights include: - The importance of Value-Based Pricing (VBP) in aligning financial investments with patient benefits. - How AI and data analytics streamline drug development, providing predictive insights and enhancing stakeholder engagement. - The role of adaptive clinical trials and real-world evidence (RWE) in reducing costs and improving the efficiency of bringing new therapies to market. Read the full article to explore how they’re helping shape a more sustainable and patient-focused future in life sciences: https://lnkd.in/ge8j9dkX #LifeSciences #Innovation #Healthcare #Pharmaceuticals #AI #DataAnalytics #CostValue #PatientCare

With the cost of bringing therapeutics to market doubling in recent years, and the introduction of high cost cell and gene therapies to the market, the pharmaceutical and healthcare industries have been forced to develop innovative solutions to strike a balance between costs and value to patients. In our article, Paul Archer, Daniel Cummings, and I discuss new strategies in mitigating costs, maximizing ROI, and building a sustainable, patient-focused future in life sciences. 👇🏻Click below to learn more!👇🏻

If you saw WhizAI at #pharmausa last year, just wait until you see ExplAIn this year! ExplAIn extends the power of Generative AI to uncover anomalies and key drivers that transform your analytics into a story through narratives across all life sciences data sources.

Authenticx partners with pharma manufacturers and life science enterprise to harness the ✨ power of conversations✨ to support patient access, brand insights, vendor management, and risk mitigation. Our technology leverages AI capabilities to aggregate and report on prevalent topics and trends. ➕ bonus: this conversation data likely already exists inside your organizations See how we work with Life Sciences to aggregate topics and trends by download our product guide ➡️ https://hubs.li/Q02GZxgM0